Identification of anti-SF3B1 autoantibody as a diagnostic marker in patients with hepatocellular carcinoma

Abstract

On these grounds, TA autoantibodies are feasible biomarkers even in the early stage of tumorigenesis [7, 9]. [...]the antibodies persist in the circulation with half-lives typically up to 30 days and are more stable outside the body than other biomarkers, which is a great advantage as an in vitro testing biomarker [7]. SF3B1 had already been confirmed as a component of TA exosomes derived from various cancers such as colorectal and ovarian cancer [39, 40]. [...]we examined whether SF3B1 is secreted as an exosomal component from HCC by analyzing exosomes derived from HCC cancer cell lines. Human serum ELISA detecting SF3B1 autoantibody with XC24p11 epitope can be used for the diagnosis of HCC The results described above implicates that SF3B1 is increased in HCC and can induce a specific autoantibody as it is secreted from cancer cells as an exosomal component. Since the characteristics of human HCC cells are similar to those of HCC model mouse [15–27], human SF3B1-specific autoantibody is also expected to be induced in human HCC patients. [...]we had screened the conformational epitopes of XC24 antibody from a cyclic peptide library to use them as detection antigen of anti-SF3B1 autoantibody.